Skip to main content
. 2022 Nov 12;12:104. doi: 10.1186/s13613-022-01077-7

Table 3.

Patient characteristics on day of Echocardiography

All (n = 94) Normal RVFWLS (≤−20%) (n = 67) Abnormal RVFWLS (> −20%) (n = 27) p value
SOFA score n (n missing)

93 (1)

8 [6, 10]

67 (0)

7 [6, 10]

26 (1)

9 [7, 10]

0.130§
Requirement for RRT on day of ECHO 12 (12.8%) 6 (9.0%) 6 (22.2%) 0.056*
Cardiac biomarkers
 hsTn I, ng/L n (n missing)

57 (37)

13 [5, 39.5]

43 (24)

9 [4, 23]

14 (13)

39.5 [9, 146]

0.032§
 hsTn T, ng/L n (n missing)

35 (59)

18 [10, 29]

22 (45)

12.5 [9.3, 19.8]

13 (14)

27 [21.5, 47]

 < 0.001§
 Abnormal troponinA n (n missing)

92 (2)

41 (44.6%)

65 (2)

21 (32.3%)

27 (0)

20 (74.1%)

 < 0.001*
 NT-proBNP, ng/L n (n missing)

84 (10)

461 [109, 1798]

58 (9)

377 [165, 947]

26 (1)

1697 [302, 23271]

0.004§
 Abnormal NT-proBNPB n (n missing)

84 (10)

53 (63.1%)

58 (9)

33 (56.9%)

26 (1)

20 (76.9%)

0.079*
Haemodynamic Parameters
 HR, bpm n (n missing)

92 (2)

79 [65, 96]

67 (0)

77 [63, 95]

25 (2)

84 [74, 99]

0.028§
 Rhythm

n (n missing)

Sinus

AF/Flutter

92 (2)

88 (95.7%)

4 (4.3%)

67 (0)

64 (95.5%)

3 (4.5%)

25 (2)

24 (96%)

1 (4%)

0.703ω
 Mean BP, mmHg n (n missing)

89 (5)

77 [71, 87]

64 (3)

79 [72, 88]

25 (2)

76 [69, 86]

0.164§
 CVP, mmHg n (n missing)

59 (35)

7 [3, 12]

45 (22)

7 [2.5, 12]

14 (13)

8.5 [4.5, 12.5]

0.485§
Drug Administration
 Vasopressors 40 (42.6%) 23 (34.3%) 17 (63%) 0.011*
 Inotropes 0 (0%) 0 (0%) 0 (0%) NA
 Anticoagulation
  Prophylactic 81 (86.2%) 61 (91%) 20 (74.1%) 0.097*
  Therapeutic 11 (11.7%) 5 (7.5%) 6 (22.2%)
  None 2 (2.1%) 1 (1.5%) 1 (3.7%)
 Paralysis 47 (50%) 34 (50.7%) 13 (48.1%) 0.285*
Ventilation
 FiO2 0.55 [0.45, 0.7] 0.5 [0.45, 0.65] 0.55 [0.45, 0.8] 0.373§
 Requirement for prone ventilation in previous 24 h 35 (37.2%) 27 (40.3%) 8 (29.6%) 0.484*
 Plateau pressure, cmH2O n (n missing)

48 (46)

25 (5.3)

34 (33)

24.6 (5.6)

14 (13)

26.1 (4.7)

0.397η
 PAP, cmH2O n (n missing)

91 (3)

26 [19, 30]

65 (2)

25 [19, 29]

26 (1)

27 [20, 31]

0.185§
 Tidal volume, ml/kg (PBW) n (n missing)

89 (5)

6.6 [5.9, 7.3]

64 (3)

6.5 [5.9, 7.2]

25 (2)

7.0 [5.9, 7.5]

0.335§
 P/F ratio n (n missing)

93 (1)

17.5 [12.9, 21.9]

67 (0)

17.5 [13.3, 21.8]

26 (1)

17.8 [12.3, 22,5]

0.918§
 PEEP, cmH2O n (n missing)

93 (1)

10 [8, 12]

66 (1)

10 [8, 12]

27 (0)

10 [6, 10]

0.110§
 Respiratory rate (/minute) 25 [21, 28] 24.6 (5.0) 24.4 (5.7) 0.887η
 Driving pressure, cmH2O n (n missing)

48 (46)

13 [11 17.75]

34 (33)

12 [10, 16.25]

14 (13)

16.5 [12, 20]

0.040§
 Dynamic compliance, ml/cmH2O n (n missing)

48 (46)

28.1 [19.1, 39.7]

34 (33)

31.2 [21.6, 40.1]

14 (13)

21.2 [16.5, 35.1]

0.071§
 Murray lung injury score n (n missing)

82 (12)

2.8 [2.3, 3]

58 (9)

2.8 [2.2, 3]

24 (3)

2.8 [2.35, 3.2]

0.479§

Data are presented as mean (SD), median [IQR] or n (%). Data are complete unless indicated by n (n missing)

A, hsTnT ≥ 15 ng L−1 or hsTnI ≥ 34 ng L−1 for males; ≥ 16 ng L−1 for females. B, NT-proBNP  ≥ 300 ng L−1

RVFWLS Right Ventricular Free-wall longitudinal strain, SOFA Sequential organ failure Assessment, RRT Renal Replacement Therapy, hsTn High Sensitivity Troponin, NT-proBNP N-terminal pro B-type Natriuretic Peptide, HR Heart Rate, AF Atrial Fibrillation, BP Blood Pressure; CVP Central Venous Pressure, FiO2 Fraction of Inspired Oxygen, PAP Peak Airway Pressure, PBW Predicted Body Weight, PEEP Positive End Expiratory Pressure

Between-group differences were assessed using Student’s T test (η), Mann–Whitney U test (§), Fisher’s Exact test (ω), and Pearson Chi-Square test (*)